Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 2/20 | 0.47 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.47 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.47 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | KDM6B | O15054 | 1/20 | 0.40 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449987 | 0.93 | MAPT (0.46) | KDM5AKDM4DKDM4CKDM5BKDM3A | |
| SCHEMBL6448718 | 0.89 | TRPV1 (0.47) | KDM5AKDM4DKDM4CKDM5BKDM3A | |
| SCHEMBL6449735 | 0.86 | TDP2 (0.41) | KDM5AKDM4DKDM4CKDM5BKDM3A | |
| SCHEMBL6452464 | 0.82 | GRM5 (0.45) | MAPTPOLBTP53RAB9AMEN1 | |
| SCHEMBL6452697 | 0.82 | NPC1 (0.45) | MAPTPOLBTP53RAB9AMEN1 | |
| SCHEMBL6453543 | 0.82 | NPC1 (0.46) | MAPTPOLBTP53RAB9AMEN1 | |
| SCHEMBL6456813 | 0.81 | TRPV1 (0.49) | MAPTPOLBRAB9AMEN1KMT2A | |
| SCHEMBL6467550 | 0.80 | NPC1 (0.43) | MAPTTP53RAB9ANPC1CASP3 | |
| SCHEMBL6459377 | 0.80 | NPC1 (0.43) | KDM4CMAPTTP53RAB9AMEN1 | |
| SCHEMBL6450088 | 0.80 | NPC1 (0.43) | MAPTTP53RAB9AKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | KDM5A 2845/4885KDM4D 3453/4885KDM4C 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.